Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0052 in advanced solid tumors
NCT06992687Phase 2Enrolling by invitation
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HB0052 in solid tumor, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Sep 2024; status: enrolling by invitation.
02
Drugs
HB0052
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06992687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992687.